Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04848337 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
A Phase 2 study of Neuroendocrine Tumors and Prostate Cancer Metastatic, sponsored by University of Michigan Rogel Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT04848337 is a Phase 2 study of Neuroendocrine Tumors and Prostate Cancer Metastatic that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 45 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04848337, a Phase 2 study of Neuroendocrine Tumors and Prostate Cancer Metastatic, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (5)
California
- City of Hope - Duarte
Georgia
- Winship Cancer Instituted of Emory University - Atlanta
Michigan
- University of Michigan Health System - Ann Arbor
Oregon
- Oregon health - Portland
Wisconsin
- Froedtert and The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04848337
The ClinicalTrials.gov registry entry for NCT04848337 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (75% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04848337 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT04848337 about?
NCT04848337 is a clinical study titled "Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer". Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On D...
What is the current status of trial NCT04848337?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2021-05-25. Estimated completion is 2026-04.
What conditions does trial NCT04848337 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Prostate Cancer Metastatic.
What interventions are being tested in trial NCT04848337?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04848337?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04848337 being conducted?
This trial has 5 study locations across California, Georgia, Michigan, Oregon, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.